We’re pleased to announce that Advent has acquired a majority shareholding in NZCR Group in partnership with our existing shareholders.
For more than 35 years, NZCR has delivered complex early and later-phase clinical trials across New Zealand and Australia, partnering with global pharmaceutical, biotechnology and contract research organisations to help advance new medicines and treatments. Through our NZCR, CMAX, Optimal and Fusion brands, we’ve built one of Australasia’s most established clinical research networks.
This investment marks an exciting new chapter for NZCR. By combining our local expertise with Advent’s global reach and resources, we look forward to creating new opportunities for sponsors, researchers and participants across the region while continuing to strengthen our international presence.
Most importantly, our commitment remains unchanged: delivering high-quality clinical research and exceptional experiences for our participants, sponsors, investigators and partners as we continue advancing health outcomes.
Read more here: https://www.nzcr.co.nz/nzcr-group-acquisition-advent-pdf